1 / 1

Unplanned 30-Day Readmission Risk Among Patients with Acute Myocardial Infarction:

Table 2. Timing of ADP receptor inhibitor switch. Unplanned 30-Day Readmission Risk Among Patients with Acute Myocardial Infarction: a Report from TRANSLATE-ACS Connie N. Hess, MD 1 ; Tracy Y. Wang, MD, MHS 1 ; Lisa McCoy 1 ; Emily Honeycutt 1 ;

jared
Download Presentation

Unplanned 30-Day Readmission Risk Among Patients with Acute Myocardial Infarction:

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Table 2. Timing of ADP receptor inhibitor switch Unplanned 30-Day Readmission Risk Among Patients with Acute Myocardial Infarction: a Report from TRANSLATE-ACS Connie N. Hess, MD1; Tracy Y. Wang, MD, MHS1; Lisa McCoy1; Emily Honeycutt1; John C. Messenger, MD2; William T. Smith IV, MD3; Marjorie E. Zettler, PhD, MPH4, Mark B. Effron, MD4; Timothy D. Henry, MD5; Eric D. Peterson, MD, MPH1; Gregg C. Fonarow, MD6 1Duke Clinical Research Institute; 2Denver VA Medical Center; 3New Hanover Regional Medical Center; 4Lilly USA, LLC; 5Minneaopolis Heart Institute Foundation at Abbott Northwestern Hospital; 6UCLA Medical Center Results Background • Hospital readmissions after acute myocardial infarction (AMI) are a Medicare hospital performance measure. • Current readmission models have relied on administrative data, have included planned readmissions, and/or have examined limited patient populations and risk factors. Table 2. Factors associated with 30-day unplanned readmission Table 1. Patient characteristics • Overall 30-day readmission: 12.4% (n=1027) • Unplanned readmission: 8.8% (n=730) vs. planned readmission: 3.9% (n=324) Figure 1. Causes of unplanned 30-day readmission Objectives • To examine the incidence and causes of unplanned readmission within 30 days of discharge among AMI patients treated with percutaneous coronary intervention (PCI). • To identify factors associated with unplanned 30-day readmissions. Methods Figure 2. Variation in readmissions among hospitals • Data Source • TRANSLATE-ACS (TReatment with ADP receptor iNhibitorS: Longitudinal Assessment of Treatment Patterns and Events after Acute Coronary Syndrome) observational registry • Patient population • 8265 AMI patients treated with PCI and ADP inhibitor and discharged home alive from 216 hospitals between 4/2010 and 8/2012 with complete baseline, 6 week follow-up, and hospital billing data • Statistics • Death within 30 days of discharge censored • Cardiovascular and bleeding readmissions identified using primary ICD-9 billing codes • Multivariable logistic regression to identify factors significantly associated with unplanned 30-day readmission Limitations • Hospitals participating in TRANSLATE perhaps not representative • Case report form may not capture all factors related to unplanned readmission • Residual measured or unmeasured confounding may account for some of these findings Median 11.5% (IQR 5.6%, 16.7%) Overall readmissions (%) Unplanned readmissions (%) Conclusions Hospital site • Unplanned 30-day readmissions occur after AMI in 1 in 11 patients. • The majority of unplanned readmissions are non-cardiovascular. • Rates of readmission vary among hospitals. • Clinical, socio-demographic, and functional variables may identify patients at higher risk for unplanned readmissions and allow for targeted strategies to reduce rehospitalizations. Hospital site Median 2.0% (IQR 0.0%, 5.9%) Median 8.0% (IQR 2.3%, 12.3%) Planned readmissions (%) Author disclosures: C.N. Hess, None; T.Y. Wang, Bristol-Myers Squibb/Sanofi Aventis Partnership, Significant, Research Grant; Schering Plough/Merck & Co., Significant, Research Grant; The Medicines Co., Significant, Research Grant; Heartscape Technologies, Inc., Significant, Research Grant; Canyon Pharmaceuticals, Significant, Research Grant; Eli Lilly/Daiichi Sankyo Alliance, Significant, Research Grant; Medco Health Solutions, Inc., Modest, Honoraria; Astrazeneca, Modest, Honoraria; American College of Cardiology Foundation, Modest,Honoraria; L. Kaltenbach, None; E. Honeycutt, None; J.C. Messenger, None; W.T. Smith, None; M.E. Zettler, Eli Lilly, Significant, Employment; M.B. Effron, Eli Lilly, Significant, Employment; Eli Lilly, Significant, Ownership Interest; T.D. Henry, Eli Lilly, Significant, Research Grant; Daiichi, Significant, Research Grant; Eli Lilly, Modest, Consultant/Advisory Board; Daiichi, Modest, Consultant/Advisory Board; E.D. Peterson, Eli Lilly, Significant, Research Grant; Janssen Pharmaceuticals, Significant, Research Grant; G.C. Fonarow, None. Hospital site

More Related